公开(公告)号：WO2009155021A2

公开(公告)日：2009-12-23

申请号：PCT/US2009045385

申请日：2009-05-28

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  BAIRSTOW SHAWN F

Inventor： BAIRSTOW SHAWN F

IPC: G01N33/50

CPC classification number: G01N33/5308 ,  G01N33/566 ,  G01N2400/40

Abstract: Methods and assays for oversulfated glycosaminoglycans are provided. In an embodiment, the present disclosure provides a method for detecting oversulfated glycosaminoglycan (OS-GAG) in a heparin sample. The method comprises placing the heparin sample onto a support comprising immobilized heparin and contacting the heparin sample on the support with a binding compound that attaches to the heparin and forms a heparin-binding compound complex. The binding compound also has a greater affinity for attaching to the OS-GAG than to the heparin in the heparin sample and forms an OS-GAG-binding compound complex. The method can further comprise detecting an amount of the heparin-binding compound complex on the support, and determining an amount of OS-GAG in the heparin sample based on the amount of the heparin-binding compound complex on the support.

Abstract translation: 提供过硫酸糖胺聚糖的方法和测定。 在一个实施方案中，本公开提供了在肝素样品中检测过硫酸化糖胺聚糖（OS-GAG）的方法。 该方法包括将肝素样品置于包含固定化肝素的载体上，并使载体上的肝素样品与附着于肝素的结合化合物接触并形成肝素结合复合物。 与肝素样品中的肝素相比，结合化合物对于附着于OS-GAG具有更大的亲和性，并形成OS-GAG结合复合物。 该方法可以进一步包括检测支持物上的肝素结合化合物复合物的量，并且基于支持物上的与肝素结合的化合物复合物的量来确定肝素样品中的OS-GAG的量。

公开(公告)号：AU2011280907A1

公开(公告)日：2013-02-07

申请号：AU2011280907

申请日：2011-07-22

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： BAIRSTOW SHAWN F ,  HUTSELL JENNIFER ,  RAMACHANDRAN SINDHU

IPC: C07K14/81

Abstract: The present invention provides compositions and pharmaceutical formulations of lalp derived from plasma. Also provided are methods for the manufacture of the lalp compositions and formulations, as well as method for the treatment of diseases associated with lalp dysfunction.

公开(公告)号：SG176055A1

公开(公告)日：2011-12-29

申请号：SG2011083789

申请日：2010-05-13

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： RABINOW BARRETT ,  BAIRSTOW SHAWN F ,  CHAUBAL MAHESH V ,  LEE SARAH ,  WERLING JANE

Abstract: The present disclosure is directed to surface-modified particles and to methods of making and using the same. The surface-modified particles comprise a particle core and a coating associated with the particle core, wherein the particle core comprises an active agent, the coating comprises a surfactant having formula (I) or a salt thereof, and the surface-modified particle has an average size from about 1 nm to about 2,000 nm:

公开(公告)号：AU2010249008A1

公开(公告)日：2011-12-01

申请号：AU2010249008

申请日：2010-05-13

Applicant: BAXTER HEALTHCARE SA ,  BAXTER INT

Inventor： BARRETT RABINOW ,  BAIRSTOW SHAWN F ,  CHAUBAL MAHESH V ,  SARAH LEE ,  JANE WERLING

IPC: A61K9/14 ,  A61K31/337 ,  A61K47/34 ,  A61P35/00

Abstract: The present disclosure is directed to surface-modified particles and to methods of making and using the same. The surface-modified particles comprise a particle core and a coating associated with the particle core, wherein the particle core comprises an active agent, the coating comprises a surfactant having formula (I) or a salt thereof, and the surface-modified particle has an average size from about 1 nm to about 2,000 nm:

公开(公告)号：CA2761801C

公开(公告)日：2018-01-02

申请号：CA2761801

申请日：2010-05-13

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： RABINOW BARRETT ,  BAIRSTOW SHAWN F ,  CHAUBAL MAHESH V ,  LEE SARAH ,  WERLING JANE

IPC: A61K9/14 ,  A61K31/337 ,  A61P35/00

Abstract: The present disclosure is directed to surface-modified particles and to methods of making and using the same. The surface-modified particles comprise a particle core and a coating associated with the particle core, wherein the particle core comprises an active agent, the coating comprises a surfactant having formula (I) or a salt thereof, and the surface-modified particle has an average size from about 1 nm to about 2,000 nm:

公开(公告)号：BRPI0922658A2

公开(公告)日：2016-01-05

申请号：BRPI0922658

申请日：2009-12-18

Applicant: BAXTER HEALTHCARE SA ,  BAXTER INT

Inventor： RAUSA FRANCISCO M III ,  MIN KYUNGYOON ,  BACKES LARRY ,  POKROPINSKI SHARON ,  BAIRSTOW SHAWN F ,  RAMACHANDRAN SINDHU

IPC: A61M1/34 ,  A61M1/36

公开(公告)号：AU2013203048A1

公开(公告)日：2014-10-02

申请号：AU2013203048

申请日：2013-04-09

Applicant: BAXTER HEALTHCARE SA ,  BAXTER INT

Inventor： BAIRSTOW SHAWN F ,  RAMACHANDRAN SINDHU ,  JOHNSON RICHARD ,  SCHILL NICHOLAS J

IPC: C07K1/14 ,  A61K31/00 ,  C07K14/435

Abstract: Among other aspects, the present disclosure provides methods for preparing enriched compositions of plasma-derived Factor H from fractions formed during the manufacturing processes of established plasma-derived therapeutic compositions. Specifically, methods are provided for the isolation of Factor H from Fraction precipitates commonly discarded during the manufacture of commercial IgG therapeutics. Advantageously, the Factor H compositions prepared according to these methods have improved proteolytic profiles and reduced amidolytic activity.

公开(公告)号：AU2009327420A1

公开(公告)日：2011-07-14

申请号：AU2009327420

申请日：2009-12-18

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： KYUNGYOON MIN ,  LARRY BACKES ,  RAUSA III FRANCISCO M ,  BAIRSTOW SHAWN F ,  SINDHU RAMACHANDRAN ,  SHARON POKROPINSKI

IPC: A61M1/34 ,  A61M1/36

Abstract: The present disclosure relates generally to systems for obtaining a pharmaceutically acceptable immunoglobulin from blood of a donor comprising a first conduit configured to convey blood from the donor to a substrate, wherein said blood includes at least one first component and at least one second component, said first component of the blood including immunoglobulin, and wherein said substrate is adapted to bind immunoglobulin; and a second conduit configured to convey at least a portion of the second component of the blood from the first conduit to the donor.

公开(公告)号：CO6680653A2

公开(公告)日：2013-05-31

申请号：CO13035387

申请日：2013-02-21

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： BAIRSTOW SHAWN F ,  HUTSELL JENNIFER ,  RAMACHANDRAN SINDHU

IPC: C07K14/81

Abstract: La presente invención proporciona las composiciones y formulaciones farmacéuticas de lalp derivada del plasma. Se proporciona además la fabricación de las composiciones y formulaciones de lalp, así como el método para el tratamiento de las enfermedades asociadas con la disfunción de lalp.Un método para preparar una composición de lalp enriquecida a partir de plasma, el método comprende las etapas de: (a) proporcionar una fracción de plasma crio-pobre; (b) precipitar lalp de la fracción de plasma crio-pobre con al menos una primera reacción de precipitación con etanol para formar un precipitado que contiene lalp; y (c) extraer lalp del precipitado que contiene IaIp, formando de ese modo una composición de lalp enriquecida; en donde él precipitado de lalp se selecciona del grupo que consiste de una torta de filtro de la Fracción II+III, un precipitado de la Fracción I, un precipitado de la Fracción I+II+III, un precipitado de la Fracción II+III, Fracción IV-1, un precipitado A de Kistler-Nitschmann, y un precipitado B de Kistler-Nitschmann.Métodos para la co-fabricación de lalp y Factor H a partir de fraccionamientos de plasma desechados de cualquier otra forma durante la fabricación de otras composiciones de factor de la sangre.

公开(公告)号：MX2011012196A

公开(公告)日：2013-05-30

申请号：MX2011012196

申请日：2010-05-13

Applicant: BAXTER INT

Inventor： WERLING JANE ,  BAIRSTOW SHAWN F ,  RABINOW BARRETT ,  CHAUBAL MAHESH V ,  LEE SARAH

IPC: A61K31/337 ,  A61K9/14 ,  A61K47/34 ,  A61P35/00

Abstract: La presente invención está dirigida a partículas de superficie modificada y a métodos para hacer y utilizar las mismas. Las partículas de superficie modificada comprenden un núcleo de partícula y un revestimiento asociado con el núcleo de partícula, en donde el núcleo de partícula comprende un agente activo, el revestimiento comprende un agente tensoactivo que tienen la fórmula (I) o una sal del mismo, y la partícula de superficie modificada tiene un tamaño promedio de aproximadamente 1 nm a aproximadamente 2,000 nm.